78 results on '"Magro, B"'
Search Results
2. Transjugular intrahepatic portosystemic shunt after liver transplantation: is patient selection the key to success?
- Author
-
Leonardi, F., Magro, B., Maruzzelli, L., Pasulo, L., Marra, P., Petridis, I., Pinelli, D., Miraglia, R., Fagiuoli, S., and Gruttadauria, S.
- Published
- 2024
- Full Text
- View/download PDF
3. The IMPROVEMENT project: first report of the global liver transplant activity
- Author
-
Avolio, A.W., Pascale, M.M., Burra, P., Bhoori, S., De Maria, N., Donato, F., Fagiuoli, S., Lanza, A. Galeota, Giannelli, V., Ginanni Corradini, S, Lenci, I., Magro, B., Martini, S., Petruccelli, S., Piscaglia, F., Pompili, M., Rendina, M., Baroni, G.L. Svegliati, Violi, P., Barbier, L., Braun, F., Boin, I., Caccamo, L., Cicarelli, O., Cillo, U., Carraro, A., Cescon, M., De Carlis, L., De Carlis, R, De Simone, P., De Santibanes, M., Deng, F., Benedetto, F. Di, Ettorre, G.M., Fernandez, H., Gastaca, M., Gruttadauria, S., Guo, Z., Hammond, J., Lai, Q, Lesurtel, M., Llado, L., Martins, P., Mazzaferro, V., Mejia, G., Nadalin, S., Oniscu, G., Patel, M., Perera, T., Pinelli, D., Polak, W., Quintini, C., Ravaioli, M., Rela, M., Romagnoli, R., Salame, E, Subash, G., Tandoi, F., Takashi, I., Timucin, T., Tisone, G., Vennarecci, G., Vivarelli, M., Vorasittha, A., Zieniewicz, K., and Agopian, V.
- Published
- 2024
- Full Text
- View/download PDF
4. Impact of laparoscopic liver resection for access to the waiting list of a single regional liver transplant center in southern Italy: entry and dropout flows’ analysis
- Author
-
Pagano, D., Vella, R., Calamia, S., di Francesco, F., Petri, S. Li, Bonsignore, P., Tropea, A., Accardo, C., Vella, I., Magro, B., Laquatra, N., Lorenzo, N. Di, Barbara, M., and Gruttadauria, S.
- Published
- 2023
- Full Text
- View/download PDF
5. Serum procalcitonin predicts mortality independently of the presence of ACLF in patients with cirrhosis and ascites hospitalized for suspicious infection and treated with empiric antibiotic therapy
- Author
-
Bianchini, M., Celsa, C., Magro, B., Cavani, G., Giuffrida, P., Battaglia, S., Saltini, D., Zanetto, A., Indulti, F., Guasconi, T., Girardis, M., Calvaruso, V., Fagiuoli, S., Colecchia, A., Villa, E., Cammà, C., and Schepis, F.
- Published
- 2023
- Full Text
- View/download PDF
6. Transvaginal endoscopy: new technique evaluating female infertility. Three Mediterranean countries’ experiences
- Author
-
Tanos, V., Bigatti, G., Paschopoulos, M., Rosales, M., Magro, B., Gianaroli, L., Ioannou, D., Avgoustatos, F., and Lolis, D. E.
- Published
- 2005
- Full Text
- View/download PDF
7. BOC.01.8: TRANS JUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT AFTER LIVER TRANSPLANTATION: IS PATIENT SELECTION THE KEY TO SUCCESS?
- Author
-
Magro, B., Leonardi, F., Maruzzelli, L., Pasulo, L., Marra, P., Pinelli, D., Miraglia, R., Gruttadauria, S., and Fagiuoli, S.
- Published
- 2024
- Full Text
- View/download PDF
8. OC.15.6 SERUM MICRORNA PREDICT FIBROSIS IN LIVER TRANSPLANT RECIPIENTS WITH HCV RECURRENCE AFTER TREATMENT WITH DAAS: A PILOT STUDY
- Author
-
Magro, B., Barbera, F., Seidita, A., Tuzzolino, F., Gruttadauria, S., Conaldi, P.G., and Pietrosi, G.
- Published
- 2022
- Full Text
- View/download PDF
9. Clinical features of patients with new onset of autoimmune hepatitis following SARS-CoV-2 vaccination
- Author
-
Rigamonti, C., Coco, B., Brunetto, M., Labanca, S., Giannini, E.G., Magro, B., Fagiuoli, S., Baroni, G. Svegliati, Sgamato, C., Miele, L., Grieco, A., Giuli, L., Manfredi, G.F., and Pirisi, M.
- Published
- 2022
- Full Text
- View/download PDF
10. AFP at transplant is associated with a higher risk of HCC recurrence after liver transplantation for patients meeting Milano criteria
- Author
-
Magro, B., Pinelli, D., De Giorgio, M., Ghirardi, A., Giuseppe, B., Del Prete, L., Colledan, M., and Fagiuoli, S.
- Published
- 2021
- Full Text
- View/download PDF
11. Developmental programming: intrauterine caloric restriction promotes upregulation of mitochondrial sirtuin with mild effects on oxidative parameters in the ovaries and testes of offspring.
- Author
-
Dal Magro, B. M., Stone, V., Klein, C. P., Maurmann, R. M., Saccomori, A. B., dos Santos, B. G., August, P. M., Rodrigues, K. S., Conrado, L., de Sousa, F. A. B., Dreimeier, D., Mello, F., and Matté, C.
- Subjects
- *
LOW-calorie diet , *GONADS , *GENITALIA , *OVARIES , *TESTIS , *PREMATURE ovarian failure - Abstract
According to the developmental origins of health and disease (DOHaD) hypothesis, changes in the maternal environment are known to reprogram the metabolic response of offspring. Known for its redox modulation, caloric restriction extends the lifespan of some species, which contributes to diminished cellular damage. Little is known about the effects of gestational caloric restriction, in terms of antioxidant parameters and molecular mechanisms of action, on the reproductive organs of offspring. This study assessed the effects of moderate (20%) caloric restriction on redox status parameters, molecular expression of sirtuin (SIRT) 1 and SIRT3 and histopathological markers in the ovaries and testes of adult rats that were subjected to gestational caloric restriction. Although enzyme activity was increased, ovaries from female pups contained high levels of oxidants, whereas testes from male pups had decreased antioxidant enzyme defences, as evidenced by diminished glyoxalase I activity and reduced glutathione content. Expression of SIRT3, a deacetylase enzyme related to cellular bioenergetics, was increased in both ovaries and testes. Previous studies have suggested that, in ovaries, diminished antioxidant metabolism can lead to premature ovarian failure. Unfortunately, there is little information regarding the redox profile in the testis. This study is the first to assess the redox network in both ovaries and testes, suggesting that, although intrauterine caloric restriction improves molecular mechanisms, it has a negative effect on the antioxidant network and redox status of reproductive organs of young adult rats. Interventions during pregnancy can have effects throughout life, a concept known as metabolic programming. This study is the first to assess the antioxidant content in reproductive organs of animals subjected to caloric restriction (CR) during intrauterine development. CR is known to diminish food intake without impairing nutrient consumption. Although known to prolong the lifespan in some species, CR may have a major role in modulating the antioxidant defences of germline cells in adults of reproductive age. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. T06.01.2 ESBLE AND MRSA FAECAL CARRIAGE IN CIRRHOTIC PATIENTS: A RETROSPECTIVE STUDY ON CLINICAL OUTCOMES BEFORE AND AFTER LIVER TRANSPLANTATION
- Author
-
Magro, B., Mazzola, A., Munteanu, M., Goumard, C., Martinez, V., Bernard, D., Scatton, O., Cammà, C., and Conti, F.
- Published
- 2020
- Full Text
- View/download PDF
13. T03.01.13 DIAGNOSTIC PERFORMANCE OF ENDOSCOPIC ULTRASOUND THROUGH-THE-NEEDLE MICROFORCEPS BIOPSY (EUS-TTNB) OF PANCREATIC CYSTIC LESIONS: A SYSTEMATIC REVIEW WITH META-ANALYSIS
- Author
-
Tacelli, M., Celsa, C., Magro, B., Barresi, L., Capurso, G., Arcidiacono, P.G., Cammà, C., and Crinò, S.F.
- Published
- 2020
- Full Text
- View/download PDF
14. ESBLE and MRSA carriage in cirrhotic patients: a retrospective study on clinical outcomes before and after liver transplantation
- Author
-
Magro, B., Mazzola, A., Munteanu, M., Goumard, C., Martinez, V., Bernard, D., Scatton, O., Cammà, C., and Conti, F.
- Published
- 2020
- Full Text
- View/download PDF
15. P.07.42 ENDOSCOPY AND INFLAMMATORY BOWEL DISEASE: DATA FROM A PILOT EXPERIENCE TO INVESTIGATE THE GAP BETWEEN THE CURRENT GUIDELINES AND THE REAL CLINICAL PRACTICE
- Author
-
Mocciaro, F., Magro, B., Conte, E., Bonaccorso, A., and Di Mitri, R.
- Published
- 2019
- Full Text
- View/download PDF
16. P.05.13 THE IMPACT OF “CENTRALIZED OUTPATIENT BOOKING OFFICE” ON COLONOSCOPY OUTCOMES: A REAL-LIFE PILOT STUDY
- Author
-
Mocciaro, F., Di Mitri, R., Conte, E., Magro, B., Bonaccorso, A., and Boemi, R.
- Published
- 2019
- Full Text
- View/download PDF
17. P.01.22 A NATIONAL SURVEY ON GASTROENTEROLOGY TRAINING IN ITALY: CURRENT LANDSCAPE AND FUTURE NEEDS
- Author
-
Paduano, D., Magro, B., Antonelli, G., Guarracino, M., Tapete, G., Savarino, E., Maida, M., and Ianiro, G.
- Published
- 2019
- Full Text
- View/download PDF
18. OC.08.2 RISK FACTORS FOR RELAPSE AND ROLE OF MAINTENANCE STEROID TREATMENT IN PATIENTS WITH AUTOIMMUNE PANCREATITIS: SYSTEMATIC REVIEW AND META-ANALYSIS
- Author
-
Tacelli, M., Magro, B., Celsa, C., Barresi, L., Guastella, S., Capurso, G., Frulloni, L., Cabibbo, G., and Cammà, C.
- Published
- 2019
- Full Text
- View/download PDF
19. OC.07.1 DIRECT ACTING ANTIVIRALS AFTER SUCCESSFUL TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA IMPROVE SURVIVAL AND REDUCE HEPATIC DECOMPENSATION IN HCV-CIRRHOTIC PATIENTS
- Author
-
Celsa, C., Cabibbo, G., Calvaruso, V., Petta, S., Cacciola, I., Cannavò, M.R., Madonia, S., Rossi, M., Magro, B., Rini, F., Distefano, M., Larocca, L., Prestileo, T., Malizia, G., Bertino, G., Benanti, F., Licata, A., Scalisi, I., Mazzola, G., Di Rosolini, M.A., Alaimo, G., Averna, A., Cartabellotta, F., Alessi, N., Guastella, S., Russello, M., Scifo, G., Squadrito, G., Raimondo, G., Craxì, A., Di Marco, V., and Cammà, C.
- Published
- 2019
- Full Text
- View/download PDF
20. PC.01.10 LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT
- Author
-
Magro, B., Calvaruso, V., Petta, S., Cacciola, I., Cabibbo, G., Cartabellotta, F., Di Rosolini, A., Davì, A., Cannavò, M., Russello, M., Di Stefano, M., Scifo, G., Di Lorenzo, F., Prestileo, T., Rocca, L. La, Montineri, A., Fuduli, G., Digiacomo, A., Cannizzaro, M., Madonia, S., Licata, A., Malizia, G., Alaimo, G., Bertino, G., Cacopardo, B., Iacobello, C., Averna, A., Guarneri, L., Scalisi, I., Mazzola, G., Mondello, L., Portelli, V., Squadrito, G., Cammà, C., Raimondo, G., Craxì, A., and Di Marco, V.
- Published
- 2019
- Full Text
- View/download PDF
21. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
- Author
-
Cabibbo, G., Celsa, C., Calvaruso, V., Petta, S., Cacciola, I., Cannavò, M.R., Madonia, S., Rossi, M., Magro, B., Rini, F., Distefano, M., Larocca, L., Prestileo, T., Malizia, G., Bertino, G., Benanti, F., Licata, A., Scalisi, I., Mazzola, G., Di Rosolini, M.A., Alaimo, G., Averna, A., Cartabellotta, F., Alessi, N., Guastella, S., Russello, M., Scifo, G., Squadrito, G., Raimondo, G., Craxì, A., Di Marco, V., and Cammà, C.
- Published
- 2019
- Full Text
- View/download PDF
22. HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy
- Author
-
Bronte, F., Calvaruso, V., Ferraro, D., Petta, S., Magro, B., Di Marco, V., and Craxì, A.
- Published
- 2018
- Full Text
- View/download PDF
23. High rate of misclassification of fibrosis stage using transient elastography thresholds to prioritize HCV patients for antiviral treatment
- Author
-
Calvaruso, V., Bronte, F., Magro, B., Conte, E., Petta, S., Cabibi, D., Craxì, A., Cammà, C., and Di Marco, V.
- Published
- 2017
- Full Text
- View/download PDF
24. A Software Product Line Definition for Validation Environments.
- Author
-
Magro, B., Garbajosa, J., and Perez, J.
- Published
- 2008
- Full Text
- View/download PDF
25. Automated integrated support for requirements-area and validation processes related to system development.
- Author
-
Alarcon, P.P., Garbajosa, J., Crespo, A., and Magro, B.
- Published
- 2004
- Full Text
- View/download PDF
26. Transesophageal echocardiography and intracardiac echocardiography differently predict potential technical challenges or failures of interatrial shunts catheter-based closure.
- Author
-
Rigatelli G, Cardaioli P, Braggion G, Aaggio S, Giordan M, Magro B, Nascimben A, Favaro A, Rincon L, Rigatelli, Gianluca, Rigateli, Gianluca, Cardaioli, Paolo, Braggion, Gabriele, Aggio, Silvio, Giordan, Massimo, Magro, Beatrice, Nascimben, Alberto, Favaro, Alberto, Roncon, Loris, and Rincon, Loris
- Abstract
We sought to prospectively assess the role of transesophageal (TEE) and intracardiac echocardiography (ICE) in detecting potential technical difficulties or failures in patients submitted to interatrial shunts percutaneous closure. We prospectively enrolled 46 consecutive patients (mean age 35+/-28, 8 years, 30 female) referred to our center for catheter-based closure of interatrial shunts. All patients were screened with TEE before the intervention. Patients who met the inclusion criteria underwent ICE study before the closure attempt (40 patients). TEE detected potential technical difficulties in 22.5% (9/40) patients, whereas ICE detected technical difficulties in 32.5% (13/40 patients). In patients with positive TEE/ICE the procedural success (92.4% versus 100% and, P = ns) and follow-up failure rate (7.7% versus 0%, P = ns) were similar to patients with negative TEE/ICE, whereas the fluoroscopy time (7 +/- 1.2 versus 5 +/- 0.7 minutes, P < 0.03), the procedural time (41 +/- 4.1 versus 30 +/- 8.2 minutes, P +/- 0.03), and technical difficulties rate (23.1% versus 0%, P = 0.013) were higher. Differences between ICE and TEE in the evaluation of rims, measurement of ASD or fossa ovalis, and detection of venous valve and embryonic septal membrane remnants impacted on technical challenges and on procedural and fluoroscopy times but did not influence the success rate and follow-up failure rate. [ABSTRACT FROM AUTHOR]
- Published
- 2007
27. Parallel programming with message passing and directives.
- Author
-
Bova, S.W., Breshears, C.P., Gabb, H., Kuhn, B., Magro, B., Eigenmann, R., Gaertner, G., Salvini, S., and Scott, H.
- Published
- 2001
- Full Text
- View/download PDF
28. AA genotype of deSNP rs6726639 of MERTK gene is associated with development of Hepatocellular Carcinoma after eradication of Hepatitis C Virus infection.
- Author
-
Di Marco, L., Calvaruso, V., Grimaudo, S., Petta, S., Pipitone, M.R., Cabibbo, G., Conte, E., Magro, B., Rini, F., Celsa, C., Cammà, C., Craxì, A., and Di Marco, V.
- Published
- 2019
- Full Text
- View/download PDF
29. Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19
- Author
-
Marco Rizzi, Stefano Fagiuoli, Sandro Sironi, Tiziano Barbui, Alessandra Carobbio, Emilia D'Elia, Roberto Trevisan, Gianpaolo Mangia, Antonello Gavazzi, Michele Senni, Luca Novelli, Arianna Ghirardi, Gianluca Imeri, Roberto Cosentini, Bianca Magro, Federico Raimondi, Ferdinando Luca Lorini, Andrea Giammarresi, Giulio Balestrieri, Mariangela Amoroso, Mauro Gori, Fabiano Di Marco, Gori, M, Ghirardi, A, D'Elia, E, Imeri, G, Di Marco, F, Gavazzi, A, Carobbio, A, Balestrieri, G, Giammarresi, A, Trevisan, R, Amoroso, M, Raimondi, F, Novelli, L, Magro, B, Mangia, G, Lorini, F, Fagiuoli, S, Barbui, T, Rizzi, M, Cosentini, R, Sironi, S, and Senni, M
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Epidemiology ,business.industry ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,Angiotensin-Converting Enzyme Inhibitors ,Renin-Angiotensin System ,Renin–angiotensin system ,Immunology ,Hypertension ,Medicine ,Humans ,COVID 19, renin–angiotensin system inhibitors, angiotensin-converting enzyme 2 (ACE2) receptor ,Cardiology and Cardiovascular Medicine ,business ,Lung ,Lung function ,Aged - Published
- 2022
30. Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria
- Author
-
Andrea Gianatti, Maria Grazia Lucà, Domenico Pinelli, Giuseppe Baronio, Massimo De Giorgio, Stefano Fagiuoli, Alessandra Carrobio, Michele Colledan, Bianca Magro, Arianna Ghirardi, Franck Nounamo, Luca Del Prete, Magro, B, Pinelli, D, De Giorgio, M, Luca, M, Ghirardi, A, Carrobio, A, Baronio, G, Del Prete, L, Nounamo, F, Gianatti, A, Colledan, M, and Fagiuoli, S
- Subjects
Cancer Research ,medicine.medical_specialty ,Cirrhosis ,medicine.medical_treatment ,Liver transplantation ,Milan criteria ,Gastroenterology ,Article ,Liver disease ,Recurrence ,Internal medicine ,medicine ,HCC ,neoplasms ,RC254-282 ,Alpha fetoprotein ,Cirrhosi ,business.industry ,cirrhosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Retrospective cohort study ,alpha fetoprotein ,liver transplantation ,recurrence ,medicine.disease ,digestive system diseases ,Oncology ,Hepatocellular carcinoma ,Cohort ,Alpha-fetoprotein ,business - Abstract
Simple Summary In the setting of liver transplantation, prediction of hepatocellular carcinoma (HCC) recurrence persists as a fundamental issue, and few tools are available during the waitlist. Biological features such as alpha-fetoprotein values are strong predictors, but it is necessary to understand how we can use them. In this study, an AFP cut-off value was individuated and also its dynamic increase on the waitlist was defined as a predictor. Abstract Background and Aim: Hepatocellular carcinoma (HCC) recurrence rates after liver transplantation (LT) range between 8 and 20%. Alpha-fetoprotein (AFP) levels at transplant can predict HCC recurrence, however a defined cut-off value is needed to better stratify patients. The aim of this study was to evaluate the rate of HCC recurrence at our centre and to identify predictors, focusing on AFP. Methods: We retrospectively analysed 236 consecutive patients that were waitlisted for HCC who all met the Milan criteria from January 2001 to December 2017 at our liver transplant centre. A total of twenty-nine patients dropped out while they were waitlisted, and 207 patients were included in the final analysis. All survival analyses included the competing-risk model. Results: The mean age was 56.8 ± 6.8 years. A total of 14% were female (n = 29/207). The median MELD (model for end-stage liver disease) at LT was 12 (9–16). The median time on the waitlist was 92 (41–170) days. The HCC recurrence rate was 16.4% (n = 34/208). The mean time to recurrence was 3.3 ± 2.8 years. The median AFP levels at transplant were higher in patients with HCC recurrence (p < 0.001). At multivariate analysis, the AFP value at transplant that was greater than 25.5 ng/mL (AUC 0.69) was a strong predictor of HCC recurrence after LT [sHR 3.3 (1.6–6.81); p = 0.001]. The HCC cumulative incidence function (CIF) of recurrence at 10 years from LT was significantly higher in patients with AFP > 25.5 ng/mL [34.3% vs. 11.5% (p = 0.001)]. Moreover, an increase in AFP > 20.8%, was significantly associated with HCC recurrence (p = 0.034). Conclusions: In conclusion, in our retrospective study, the AFP level at transplant > 25.5 ng/mL and its increase greater than 20.8% on the waitlist were strong predictors of HCC recurrence after LT in a cohort of patients that were waitlisted within the Milan criteria. However further studies are needed to validate these data.
- Published
- 2021
- Full Text
- View/download PDF
31. Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use
- Author
-
Francesco Antonio Mancarella, Massimo Attanasio, Mauro Gori, Valentina Zuccaro, Antonio Gasbarrini, Matteo Tacelli, Luca Ferdinando Lorini, Laura Paris, Calogero Cammà, Federico Raimondi, Bianca Magro, Raffaele Bruno, Lorenzo Zileri, Salvatore Battaglia, Vincenzo Giuseppe Genova, Fabiano Di Marco, Ciro Celsa, Giulia Cammà, Stefano Fagiuoli, Michele Senni, Luca Novelli, Marco Enea, Magro, B, Zuccaro, V, Novelli, L, Zileri, L, Celsa, C, Raimondi, F, Gori, M, Cammà, G, Battaglia, S, Genova, V, Paris, L, Tacelli, M, Mancarella, F, Enea, M, Attanasio, M, Senni, M, Di Marco, F, Lorini, L, Fagiuoli, S, Bruno, R, Cammà, C, Gasbarrini, A, Magro, Bianca, Zuccaro, Valentina, Novelli, Luca, Zileri, Lorenzo, Celsa, Ciro, Raimondi, Federico, Gori, Mauro, Cammà, Giulia, Battaglia, Salvatore, Genova, Vincenzo Giuseppe, Paris, Laura, Tacelli, Matteo, Mancarella, Francesco Antonio, Enea, Marco, Attanasio, Massimo, Senni, Michele, Di Marco, Fabiano, Lorini, Luca Ferdinando, Fagiuoli, Stefano, Bruno, Raffaele, Cammà, Calogero, and Gasbarrini, Antonio
- Subjects
Male ,Viral Diseases ,Epidemiology ,Clinical prediction rule ,Cardiovascular Medicine ,Vascular Medicine ,Steroid Therapy ,Chronic Liver Disease ,Cohort Studies ,Medical Conditions ,Endocrinology ,Retrospective Studie ,Risk Factors ,Medicine and Health Sciences ,80 and over ,Coronary Heart Disease ,Hospital Mortality ,Aged, 80 and over ,Multidisciplinary ,Pharmaceutics ,Liver Diseases ,Hazard ratio ,Middle Aged ,Mobile Applications ,Hospitals ,Hospitalization ,Infectious Diseases ,Brier score ,Italy ,Cardiovascular Diseases ,Medicine ,Female ,Human ,Research Article ,Cohort study ,Adult ,medicine.medical_specialty ,Endocrine Disorders ,Corticosteroid Therapy ,Science ,Settore MED/12 - GASTROENTEROLOGIA ,Mobile Application ,Cardiology ,Gastroenterology and Hepatology ,Risk Assessment ,Drug Therapy ,Internal medicine ,Diabetes Mellitus ,medicine ,Humans ,Aged ,Retrospective Studies ,Receiver operating characteristic ,business.industry ,SARS-CoV-2 ,Risk Factor ,Settore MED/09 - MEDICINA INTERNA ,COVID-19 ,Covid 19 ,Retrospective cohort study ,Cardiovascular Disease Risk ,Triage ,Confidence interval ,Health Care ,ROC Curve ,Health Care Facilities ,Medical Risk Factors ,Metabolic Disorders ,Cohort Studie ,business - Abstract
Backgrounds Validated tools for predicting individual in-hospital mortality of COVID-19 are lacking. We aimed to develop and to validate a simple clinical prediction rule for early identification of in-hospital mortality of patients with COVID-19. Methods and findings We enrolled 2191 consecutive hospitalized patients with COVID-19 from three Italian dedicated units (derivation cohort: 1810 consecutive patients from Bergamo and Pavia units; validation cohort: 381 consecutive patients from Rome unit). The outcome was in-hospital mortality. Fine and Gray competing risks multivariate model (with discharge as a competing event) was used to develop a prediction rule for in-hospital mortality. Discrimination and calibration were assessed by the area under the receiver operating characteristic curve (AUC) and by Brier score in both the derivation and validation cohorts. Seven variables were independent risk factors for in-hospital mortality: age (Hazard Ratio [HR] 1.08, 95% Confidence Interval [CI] 1.07–1.09), male sex (HR 1.62, 95%CI 1.30–2.00), duration of symptoms before hospital admission https://sites.google.com/community.unipa.it/covid-19riskpredictions/c19-rp). Conclusions A validated simple clinical prediction rule can promptly and accurately assess the risk for in-hospital mortality, improving triage and the management of patients with COVID-19.
- Published
- 2021
32. Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy
- Author
-
Emanuele Nicastro, Lorenzo D' Antiga, Angelo Di Giorgio, Luisa Pasulo, Stefano Fagiuoli, Camilla Speziani, Bianca Magro, Massimo De Giorgio, Di Giorgio, A, Nicastro, E, Speziani, C, De Giorgio, M, Pasulo, L, Magro, B, Fagiuoli, S, and D' Antiga, L
- Subjects
2019-20 coronavirus outbreak ,Health Status ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,medicine.disease_cause ,Article ,Betacoronavirus ,Pandemic ,medicine ,Humans ,immunosuppression (IS) ,Autoimmune liver disease ,Pandemics ,Coronavirus ,biology ,Hepatology ,business.industry ,SARS-CoV-2 ,Liver Diseases ,autoimmune liver disease ,Outbreak ,COVID-19 ,biology.organism_classification ,Virology ,Northern italy ,Autoimmune Liver Disease (AILD) ,Italy ,Coronavirus Infections ,business - Published
- 2020
- Full Text
- View/download PDF
33. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
- Author
-
G. Cabibbo, C. Celsa, V. Calvaruso, S. Petta, I. Cacciola, M.R. Cannavò, S. Madonia, M. Rossi, B. Magro, F. Rini, M. Distefano, L. Larocca, T. Prestileo, G. Malizia, G. Bertino, F. Benanti, A. Licata, I. Scalisi, G. Mazzola, M.A. Di Rosolini, G. Alaimo, A. Averna, F. Cartabellotta, N. Alessi, S. Guastella, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, A. Craxì, V. Di Marco, C. Cammà, Cabibbo, G., Celsa, C., Calvaruso, V., Petta, S., Cacciola, I., Cannavò, M.R., Madonia, S., Rossi, M., Magro, B., Rini, F., Distefano, M., Larocca, L., Prestileo, T., Malizia, G., Bertino, G., Benanti, F., Licata, A., Scalisi, I., Mazzola, G., Di Rosolini, M.A., Alaimo, G., Averna, A., Cartabellotta, F., Alessi, N., Guastella, S., Russello, M., Scifo, G., Squadrito, G., Raimondo, G., Craxì, A., Di Marco, V., and Cammà, C.
- Subjects
Hepatology ,Gastroenterology ,DAA, Hepatocelluar carcinoma, survival, HCV cirrhosis - Abstract
Background & aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) after successful treatment of early hepatocellular carcinoma (HCC) has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation. Methods: We enrolled prospectively 163 consecutive patients with HCV-related cirrhosis and at first diagnosis of early Barcelona Clinic Liver Cancer (BCLC) 0/A HCC who had achieved a complete radiologic response after curative resection or ablation, subsequently treated with DAAs. DAA-untreated patients from ITA.LI.CA. cohort (n = 328) served as controls. After propensity-score matching, outcomes of 102 DAA-treated (DAA group) and 102 DAA-untreated patients (No DAA group) were compared. Results: In DAA group, 7/102 patients (6.9%) died, HCC recurred in 28/102 patients (27.5%) and hepatic decompensation occurred in 6/102 patients (5.9%), after a mean follow-up of 21.4 months. OS was significantly higher in DAA group compared with No DAA group (hazard ratio [HR] = 0.39; 95% confidence Interval [CI] = 0.17–0.91, p = 0.03). HCC recurrence was not significantly different between DAA and No DAA groups (HR = 0.70; 95%CI = 0.44–1.13, p = 0.15). A significant reduction in the rate of hepatic decompensation was observed in DAA group compared with No DAA group (HR = 0.32; 95%CI = 0.13-0.84, p = 0.02). In DAA group, sustained virologic response was a significant predictor of overall survival (HR 0.02, 95%CI 0.00–0.19, p < 0.001), HCC recurrence (HR 0.25, 95%CI 0.11–0.57, p < 0.001) and hepatic decompensation (HR 0.12, 95%CI 0.02-0.38, p = 0.02). Conclusions: In patients with HCV-related cirrhosis and previous successful treatment of early HCC, DAAs significantly improved OS compared with No DAA treatment.
- Published
- 2019
34. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
- Author
-
A. Averna, Rete Sicilia Selezione Terapia – Hcv, Giovanni Raimondo, F. Cartabellotta, Salvatore Guastella, Giuseppe Alaimo, Vito Di Marco, Bianca Magro, Giovanni Mazzola, L. Larocca, M.R. Cannavò, Anna Licata, Gaetano Bertino, Salvatore Madonia, Irene Cacciola, Marco Distefano, Giuseppe Cabibbo, G. Scifo, N. Alessi, Giovanni Squadrito, Antonio Craxì, Franco Trevisani, Salvatore Petta, Margherita Rossi, Maurizio Russello, Francesca Rini, Calogero Cammà, Maria Antonietta Di Rosolini, Ciro Celsa, Giuseppe Malizia, Tullio Prestileo, Vincenza Calvaruso, I. Scalisi, F. Benanti, Cabibbo G., Celsa C., Calvaruso V., Petta S., Cacciola I., Cannavo M.R., Madonia S., Rossi M., Magro B., Rini F., Distefano M., Larocca L., Prestileo T., Malizia G., Bertino G., Benanti F., Licata A., Scalisi I., Mazzola G., Di Rosolini M.A., Alaimo G., Averna A., Cartabellotta F., Alessi N., Guastella S., Russello M., Scifo G., Squadrito G., Raimondo G., Trevisani F., Craxi A., Di Marco V., Camma C., and Cammà Calogero.
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Survival rate ,Carcinoma, Hepatocellular ,Cirrhosis ,Sustained Virologic Response ,Prognosi ,Hepatitis C virus (HCV), Hepatocellular carcinoma (HCC), Direct-acting antiviral (DAA), Overall survival, Prognosis, Survival rate, Liver cirrhosis ,Hepacivirus ,Antiviral Agents ,Gastroenterology ,Liver cirrhosi ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Early Hepatocellular Carcinoma ,Overall survival ,Prospective Studies ,Hepatocellular carcinoma (HCC) ,Propensity Score ,Aged ,Aged, 80 and over ,Hepatology ,business.industry ,Liver Neoplasms ,Hazard ratio ,Direct-acting antiviral (DAA) ,Hepatitis C ,Hepatitis C virus (HCV) ,Middle Aged ,medicine.disease ,Prognosis ,Liver cirrhosis ,030104 developmental biology ,Hepatocellular carcinoma ,Female ,030211 gastroenterology & hepatology ,Neoplasm Recurrence, Local ,Liver cancer ,business ,Viral hepatitis ,Follow-Up Studies - Abstract
Background & Aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation. Methods: We prospectively enrolled 163 consecutive patients with HCV-related cirrhosis and a first diagnosis of early Barcelona Clinic Liver Cancer stage 0/A HCC, who had achieved a complete radiologic response after curative resection or ablation and were subsequently treated with DAAs. DAA-untreated patients from the ITA.LI.CA. cohort (n = 328) served as controls. After propensity score matching, outcomes of 102 DAA-treated (DAA group) and 102 DAA-untreated patients (No DAA group) were compared. Results: In the DAA group, 7/102 patients (6.9%) died, HCC recurred in 28/102 patients (27.5%) and hepatic decompensation occurred in 6/102 patients (5.9%), after a mean follow-up of 21.4 months. OS was significantly higher in the DAA group compared to the No DAA group (hazard ratio [HR] 0.39; 95% CI 0.17–0.91; p = 0.03). HCC recurrence was not significantly different between the DAA and No DAA groups (HR 0.70; 95% CI 0.44–1.13; p = 0.15). A significant reduction in the rate of hepatic decompensation was observed in the DAA group compared with the No DAA group (HR 0.32; 95% CI 0.13–0.84; p = 0.02). In the DAA group, sustained virologic response was a significant predictor of OS (HR 0.02; 95% CI 0.00–0.19; p
- Published
- 2019
35. Naringin supplementation during pregnancy alters rat offspring's brain redox system and mitochondrial function.
- Author
-
Dos Santos BG, Klein CP, August PM, Crestani MS, Hozer RM, Saccomori AB, Dal Magro BM, Rodrigues KS, and Matté C
- Subjects
- Animals, Female, Pregnancy, Rats, Oxidative Stress drug effects, Animals, Newborn, Male, Flavanones pharmacology, Mitochondria drug effects, Mitochondria metabolism, Rats, Wistar, Oxidation-Reduction drug effects, Brain drug effects, Brain metabolism, Dietary Supplements, Prenatal Exposure Delayed Effects metabolism
- Abstract
Naringin supplementation is known to ameliorate oxidative stress in the central nervous system (CNS) and improve cognitive function in disease models using adult rodents. However, if this supplementation is applied during critical periods of development, would it still be beneficial? To address this question, we used pregnant Wistar rats that were supplemented daily with naringin (100 mg/kg) during gestation. After delivery, pups were euthanized on postnatal day (PND) 1, 7, and 21. The prefrontal cortex, hippocampus, striatum, and cerebellum were dissected for redox system and mitochondrial function evaluation. Our data demonstrated that naringin supplementation to pregnant rats during gestation differentially affected the brain structures analyzed, inducing a dysregulation in the redox homeostasis, mainly on PND1. Redox and mitochondrial alterations found in offspring's cerebellum on PND1 were also observed on PND7, and persisted up to PND21, indicating a higher susceptibility of this structure to the effects triggered by maternal naringin supplementation. In contrast to what was observed in the cerebellum, we found a progressive decline in the number of alterations in the prefrontal cortex, hippocampus, and striatum from PND1 up to PND21, suggesting that these brain structures are not as susceptible as the cerebellum to the naringin's effects. Thus, our findings demonstrate a possible negative programming effect triggered by maternal naringin supplementation during pregnancy in the offspring's brain, especially in the cerebellum., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2025
- Full Text
- View/download PDF
36. Maternal swimming with overload allied to postnatal high-fat, high-sugar diet induce subtle impairment on rat offspring's ovarian redox homeostasis.
- Author
-
Mariño Dal Magro B, Dos Santos BG, August PM, Menegotto MZ, Driemeier D, and Matté C
- Subjects
- Animals, Female, Rats, Pregnancy, Maternal Nutritional Physiological Phenomena, Physical Conditioning, Animal physiology, Oxidative Stress, Dietary Sugars adverse effects, Rats, Wistar, Ovary metabolism, Ovary pathology, Swimming, Oxidation-Reduction, Diet, High-Fat adverse effects, Prenatal Exposure Delayed Effects metabolism, Homeostasis
- Abstract
Context The Developmental Origins of Health and Disease (DOHaD) concept suggests that early-life interventions significantly influence the long-term health outcomes of offspring. Emerging evidence supports that maternal physical exercise and balanced nutrition can positively impact the health of the next generation. Aims This study investigated the effects of maternal swimming combined with postnatal high-fat, high-sugar (HFHS) diet on the ovarian health of adult female Wistar rat offspring. Methods Adult female Wistar rats performed swimming exercise in a controlled temperature environment (32°C, 2% bodyweight overload adjusted daily) during 4weeks, starting 1week prior mating. The female offspring received a control or HFHS diet from postnatal day (PND) 21 to PND 90. We analyzed offspring's body weight, ovarian histomorphology, redox status, and associated molecular pathways 5' adenosine monophosphate-activated protein kinase (AMPKα), forkhead box O3 (FoxO3), and mitofusin 1 (Mfn-1). Key results Our findings reveal that maternal swimming exerted an effect on offspring body weight gain, delaying it. Individually, maternal exercise reduced superoxide dismutase (SOD) activity and mitofusin-1 levels, while the postnatal HFHS diet alone decreased both SOD and glutathione peroxidase (GPx) activities and increased the pFOXO3a/FOXO3a ratio in the ovaries. Conclusions We showed that combination of maternal swimming with a 2% overload and a postnatal HFHS diet can negatively affect the ovarian redox balance in offspring. Implications Prenatal and postnatal lifestyle might affect reproductive function in females.
- Published
- 2024
- Full Text
- View/download PDF
37. Telemedicine in Patients Affected by Chronic Liver Disease: A Scoping Review of Clinical Outcomes and the Devices Evaluated.
- Author
-
Capuano P, Hileman B, Tigano S, Magro B, Lo Re V, Liotta R, Sciveres M, Ranucci G, Provenzani A, Burgio G, Scardulla C, Arcadipane A, and Martucci G
- Abstract
For patients with chronic liver disease (CLD), telemedicine is emerging as a useful tool to prevent liver decompensation or hospitalization, allowing access to and the decentralization of care, even for patients with limited resources. However, research and attendant evidence are still lacking; thus, this review aims to systematically explore the topic of telemonitoring for CLD to describe the currently used tools and clinical outcomes. The review was conducted by using key terms on PubMed/EMBASE and searching for observational studies or clinical trials (according to PRISMA recommendations) that were published between 6 April 2013 and 6 April 2023 to keep the technological framework limited to the last 10 years. The studies were described and grouped according to the aim of telemonitoring, the underlying disease, and the tools adopted to achieve remote monitoring. A total of 32 articles met the inclusion criteria. Of these, 11 articles report the successful use of a telehealth program to support and improve access to care in the management of HCV-related cirrhosis, eight articles examine the efficacy of telemedicine for remote monitoring interventions to prevent or decrease the risk of decompensation in high-risk patients, and five articles examine improvements in the physical performance and quality of life of cirrhotic patients through telehealth rehabilitation programs. Four studies were completed during the recent COVID-19 pandemic. Telehealth has the potential to provide and expand treatment access and reduce barriers to care for the most disadvantaged patients and might be able to reduce the need for hospital readmission for CLD, though most practice to test feasibility is still in the pilot stage.
- Published
- 2023
- Full Text
- View/download PDF
38. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome.
- Author
-
Efe C, Kulkarni AV, Terziroli Beretta-Piccoli B, Magro B, Stättermayer A, Cengiz M, Clayton-Chubb D, Lammert C, Bernsmeier C, Gül Ö, la Tijera FH, Anders M, Lytvyak E, Akın M, Purnak T, Liberal R, Peralta M, Ebik B, Duman S, Demir N, Balaban Y, Urzua Á, Contreras F, Venturelli MG, Bilgiç Y, Medina A, Girala M, Günşar F, Londoño MC, Androutsakos T, Kisch A, Yurci A, Güzelbulut F, Çağın YF, Avcı E, Akyıldız M, Dindar-Demiray EK, Harputluoğlu M, Kumar R, Satapathy SK, Mendizabal M, Silva M, Fagiuoli S, Roberts SK, Soylu NK, Idilman R, Yoshida EM, Montano-Loza AJ, Dalekos GN, Ridruejo E, Schiano TD, and Wahlin S
- Subjects
- Male, Humans, Female, Middle Aged, SARS-CoV-2, COVID-19 Vaccines adverse effects, ChAdOx1 nCoV-19, BNT162 Vaccine, Vaccination, COVID-19 prevention & control, Hepatitis A, Hepatitis, Autoimmune drug therapy, Hepatitis, Autoimmune etiology
- Abstract
Background and Aims: A few case reports of autoimmune hepatitis-like liver injury have been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We evaluated clinical features, treatment response and outcomes of liver injury following SARS-CoV-2 vaccination in a large case series., Approach and Results: We collected data from cases in 18 countries. The type of liver injury was assessed with the R-value. The study population was categorized according to features of immune-mediated hepatitis (positive autoantibodies and elevated immunoglobulin G levels) and corticosteroid therapy for the liver injury. We identified 87 patients (63%, female), median age 48 (range: 18-79) years at presentation. Liver injury was diagnosed a median 15 (range: 3-65) days after vaccination. Fifty-one cases (59%) were attributed to the Pfizer-BioNTech (BNT162b2) vaccine, 20 (23%) cases to the Oxford-AstraZeneca (ChAdOX1 nCoV-19) vaccine and 16 (18%) cases to the Moderna (mRNA-1273) vaccine. The liver injury was predominantly hepatocellular (84%) and 57% of patients showed features of immune-mediated hepatitis. Corticosteroids were given to 46 (53%) patients, more often for grade 3-4 liver injury than for grade 1-2 liver injury (88.9% vs. 43.5%, p = 0.001) and more often for patients with than without immune-mediated hepatitis (71.1% vs. 38.2%, p = 0.003). All patients showed resolution of liver injury except for one man (1.1%) who developed liver failure and underwent liver transplantation. Steroid therapy was withdrawn during the observation period in 12 (26%) patients after complete biochemical resolution. None had a relapse during follow-up., Conclusions: SARS-CoV-2 vaccination can be associated with liver injury. Corticosteroid therapy may be beneficial in those with immune-mediated features or severe hepatitis. Outcome was generally favorable, but vaccine-associated liver injury led to fulminant liver failure in one patient., (© 2022 American Association for the Study of Liver Diseases.)
- Published
- 2022
- Full Text
- View/download PDF
39. Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial.
- Author
-
Pagano D, Bosch J, Tuzzolino F, Oliva E, Ekser B, Zito G, Cintorino D, di Francesco F, Li Petri S, Ricotta C, Bonsignore P, Calamia S, Magro B, Trifirò G, Alduino R, Barbara M, Conaldi PG, Gallo A, Venuti F, Luca A, and Gruttadauria S
- Subjects
- Adult, Humans, Simvastatin adverse effects, Prospective Studies, Tissue Donors, Graft Survival, Treatment Outcome, Liver Transplantation adverse effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects
- Abstract
Background: The current curative approaches for ischemia/reperfusion injury on liver transplantation are still under debate for their safety and efficacy in patients with end-stage liver disease. We present the SIMVA statin donor treatment before Liver Transplants study., Methods: SIMVA statin donor treatment before Liver Transplants is a monocentric, double-blind, randomized, prospective tial aiming to compare the safety and efficacy of preoperative brain-dead donors' treatment with the intragastric administration of 80 mg of simvastatin on liver transplant recipient outcomes in a real-life setting. Primary aim was incidence of patient and graft survival at 90 and 180 d posttransplant; secondary end-points were severe complications., Results: The trial enrolled 58 adult patients (18-65 y old). The minimum follow-up was 6 mo. No patient or graft was lost at 90 or 180 d in the experimental group (n = 28), whereas patient/graft survival were 93.1% ( P = 0.016) and 89.66% ( P = 0.080) at 90 d and 86.21% ( P = 0.041) and 86.2% ( P = 0.041) at 180 d in the control group (n = 29). The percentage of patients with severe complications (Clavien-Dindo ≥IIIb) was higher in the control group, 55.2% versus 25.0% in the experimental group ( P = 0.0307). The only significant difference in liver tests was a significantly higher gamma-glutamyl transferase and alkaline phosphatase at 15 d ( P = 0.017), ( P = 0.015) in the simvastatin group., Conclusions: Donor simvastatin treatment is safe, and may significantly improve early graft and patient survival after liver transplantation, although further research is mandatory., Competing Interests: D.P. and E.O. reported receiving grants from Italian government research funding. The other authors declare no conflicts of interest. The authors hereby certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or nonfinancial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript., (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
40. How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation?
- Author
-
Pagano D, Khouzam S, Magro B, Barbara M, Cintorino D, di Francesco F, Li Petri S, Bonsignore P, Calamia S, Deiro G, Cammà C, Canzonieri M, and Gruttadauria S
- Abstract
Introduction: Hepatocellular carcinoma (HCC) accounts for nearly 90% of primary liver cancers, with estimates of over 1 million people affected by 2025. We aimed to explore the impacting role of an iterative surgical treatment approach in a cohort of HCC patients within the Milan criteria, associated with clinical risk factors for tumor recurrence (RHCC) after liver transplant (LT) and loco-regional therapies (LRT), as well as liver resection (LR) and/or microwave thermal ablation (MWTA)., Methods: We retrospectively analyzed our experience performed during an 8-year period between January 2013 and December 2021 in patients treated for HCC, focusing on describing the impact on preoperative end-stage liver disease severity, oncologic staging, tumor characteristics, and surgical treatments. The Cox model was used to evaluate variables that could predict relapse risks. Relapse risk curves were calculated according to the Kaplan-Meier method, and the log-rank test was used to compare them., Results: There were 557 HCC patients treated with a first-line approach of LR and/or LRTs ( n = 335) or LT ( n = 222). The median age at initial transplantation was 59 versus 68 for those whose first surgical approach was LR and/or LRT. In univariate analysis with the Cox model, nodule size was the single predictor of recurrence of HCC in the posttreatment setting (HR: 1.61, 95% CI: 1.05-2.47, p = 0.030). For the LRT group, we have enlightened the following clinical characteristics as significantly associated with RHCC: hepatitis B virus infection (which has a protective role with HR: 0.34, 95% CI: 0.13-0.94, p = 0.038), number of HCC nodules (HR: 1.54, 95% CI: 1.22-1.94, p < 0.001), size of the largest nodule (HR: 1.06, 95% CI: 1.01-1.12, p = 0.023), serum bilirubin (HR: 1.57, 95% CI: 1.03-2.40, p = 0.038), and international normalized ratio (HR: 16.40, 95% CI: 2.30-118.0, p = 0.006). Among the overall 111 patients with RHCC in the LRT group, 33 were iteratively treated with further curative treatment (12 were treated with LR, two with MWTA, three with a combined LR-MWTA treatment, and 16 underwent LT). Only one of 18 recurrent patients previously treated with LT underwent LR. For these RHCC patients, multivariable analysis showed the protective roles of LT for primary RHCC after IDLS (HR: 0.06, 95% CI: 0.01-0.36, p = 0.002), of the time relapsed between the first and second IDLS treatments (HR: 0.97, 95% CI: 0.94-0.99, p = 0.044), and the impact of previous minimally invasive treatment (HR: 0.28, 95% CI: 0.08-1.00, p = 0.051)., Conclusion: The coexistence of RHCC with underlying cirrhosis increases the complexity of assessing the net health benefit of ILDS before LT. Minimally invasive surgical therapies and time to HCC relapse should be considered an outcome in randomized clinical trials because they have a relevant impact on tumor-free survival., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Pagano, Khouzam, Magro, Barbara, Cintorino, di Francesco, Li Petri, Bonsignore, Calamia, Deiro, Cammà, Canzonieri and Gruttadauria.)
- Published
- 2022
- Full Text
- View/download PDF
41. Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19.
- Author
-
Gori M, Ghirardi A, D'Elia E, Imeri G, Di Marco F, Gavazzi A, Carobbio A, Balestrieri G, Giammarresi A, Trevisan R, Amoroso M, Raimondi F, Novelli L, Magro B, Mangia G, Lorini FL, Fagiuoli S, Barbui T, Rizzi M, Cosentini R, Sironi S, and Senni M
- Subjects
- Aged, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Humans, Lung, Renin-Angiotensin System, SARS-CoV-2, COVID-19, Hypertension
- Published
- 2022
- Full Text
- View/download PDF
42. Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients.
- Author
-
Gori M, Berzuini C, D'Elia E, Ghirardi A, Bernardinelli L, Gavazzi A, Balestrieri G, Giammarresi A, Trevisan R, Di Marco F, Bellasi A, Amoroso M, Raimondi F, Novelli L, Magro B, Mangia G, Lorini FL, Guagliumi G, Fagiuoli S, Parati G, and Senni M
- Subjects
- Aged, Angiotensin Receptor Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Humans, Renin-Angiotensin System, Retrospective Studies, SARS-CoV-2, Hypertension chemically induced, Hypertension complications, Hypertension drug therapy, COVID-19 Drug Treatment
- Abstract
Objectives: The effect of renin-angiotensin system inhibitors (RASIs) on mortality in patients with coronavirus disease (Covid-19) is debated. From a cohort of 1352 consecutive patients admitted with Covid-19 to Papa Giovanni XXIII Hospital in Bergamo, Italy, between February and April 2020, we selected and studied hypertensive patients to assess whether antecedent (prior to hospitalization) use of RASIs might affect mortality from Covid-19 according to age., Methods and Results: Arterial hypertension was present in 688 patients. Overall mortality (in-hospital or shortly after discharge) was 35% (N = 240). After adjusting for 26 medical history variables via propensity score matching, antecedent use of RASIs (N = 459, 67%) was associated with a lower mortality in older hypertensive patients (age above the median of 68 years in the whole series), whereas no evidence of a significant effect was found in the younger group of the same population (P interaction = 0.001). In an analysis of the subgroup of 432 hypertensive patients older than 68 years, we considered two RASI drug subclasses, angiotensin-converting enzyme inhibitors (ACEIs, N = 156) and angiotensin receptor blockers (ARBs, N = 140), and assessed their respective effects by taking no-antecedent-use of RASIs as reference. This analysis showed that both antecedent use of ACEIs and antecedent use of ARBs were associated with a lower Covid-19 mortality (odds ratioACEI = 0.57, 95% confidence interval 0.36--0.91, P = 0.018) (odds ratioARB = 0.49, 95% confidence interval 0.29--0.82, P = 0.006)., Conclusion: In the population of over-68 hypertensive Covid-19 patients, antecedent use of ACEIs or ARBs was associated with a lower all-cause mortality, whether in-hospital or shortly after discharge, compared with no-antecedent-use of RASIs., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
43. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis.
- Author
-
Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, N Assis D, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, and Wahlin S
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Hospitalization, Humans, Male, Middle Aged, Retrospective Studies, SARS-CoV-2, Young Adult, COVID-19, Hepatitis, Autoimmune complications, Hepatitis, Autoimmune drug therapy, Pharmaceutical Preparations
- Abstract
Background: We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH)., Patients and Methods: Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression., Results: We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients., Conclusion: Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
44. Impact of sarcopenia on clinical outcomes of patients undergoing simultaneous liver and kidney transplantation: a cohort study.
- Author
-
Mazzola A, Brustia R, Magro B, Atif M, Ouali N, Tourret J, Barrou B, Scatton O, and Conti F
- Subjects
- Cohort Studies, Female, Humans, Male, Middle Aged, Renal Dialysis, Treatment Outcome, Kidney Transplantation, Liver Transplantation, Sarcopenia epidemiology
- Abstract
Background: The impact of sarcopenia in patients undergoing simultaneous liver and kidney transplantation (SLKT) has not been fully delineated. The aim of this single-centre-cohort-study was to evaluate the impact of sarcopenia on the clinical outcomes., Methods: Between 2003 and 2018, 79 patients underwent SLKT. Sarcopenia was assessed via the total psoas muscle area (TPA) at the level of the 3rd. lumbar vertebra. Sarcopenia threshold was TPA < 1460 mm
2 (women) and <1560 mm2 (men). We identified post-operative biliary, vascular and digestive complications. Survival analysis was performed by the Kaplan Meier method (log-rank test)., Results: We included 43/79 SLKT recipients (56%male, median age of 58 [53-63] years). The prevalence of cirrhosis was 74% (n = 32) with median MELD-score of 21 (20-22) and that of polycystic-liver-disease was 26% (n = 11). End-stage-renal-disease of unknown origin was 36.2% (n = 12). Dialysis before transplantation was performed in 54,8% (n = 23) of patients. The median TPA was 1138 (926-1510) mm2 , and sarcopenia was detected in 72% of patients (n = 31). No difference in patient or death-censored graft-survival between sarcopenic and non-sarcopenic groups at 1 year was reported. Also, no differences at 6-months' post-transplant-complication-free and infection-free-survival rates were found., Conclusion: In this cohort of patients, no differences were observed in patients, grafts, complications or infection-free survival between sarcopenic or no sarcopenic SLKT patients. Future multi-centre studies are needed to validate and extend the generalisability of these findings., (Copyright © 2021 Elsevier Masson SAS. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
45. Successful Treatment of Suspected Donor-derived Human Herpesvirus-8 Infection in a Liver Transplant Patient With Coronavirus Disease-19.
- Author
-
Peri AM, Magro B, van den Bogaart L, Dalla Pria A, Giuffrida P, Gianatti A, Fabretti F, Maria Barbui A, Tebaldi A, Rizzi M, and Fagiuoli AS
- Subjects
- Allografts virology, COVID-19 diagnosis, COVID-19 immunology, COVID-19 therapy, Carcinoma, Hepatocellular surgery, Combined Modality Therapy methods, Cytokine Release Syndrome diagnosis, Cytokine Release Syndrome immunology, Herpesviridae Infections complications, Herpesviridae Infections diagnosis, Herpesviridae Infections transmission, Herpesvirus 8, Human isolation & purification, Humans, Liver virology, Liver Neoplasms surgery, Male, Middle Aged, Renal Dialysis, SARS-CoV-2 isolation & purification, Treatment Outcome, COVID-19 complications, Cytokine Release Syndrome therapy, Herpesviridae Infections therapy, Liver Transplantation adverse effects, Rituximab therapeutic use
- Abstract
Competing Interests: The authors declare no funding or conflicts of interest.
- Published
- 2021
- Full Text
- View/download PDF
46. Acute liver failure and HELLP syndrome: A clinical case and literature review.
- Author
-
Mazzola A, Magro B, Perdigao F, Charlotte F, Atif M, Goumard C, Scatton O, and Conti F
- Subjects
- Adult, Cesarean Section, Female, Hematoma etiology, Humans, Pregnancy, HELLP Syndrome diagnosis, Liver Diseases, Liver Failure, Acute etiology
- Abstract
Background: HELLP syndrome is a pregnancy-related liver disease associated with increased maternal and foetal mortality. In rare cases, it can lead to the development of a subcapsular hepatic haematoma as well as its rupture. This rupture is life-threatening if not urgently treated., Method: We describe a clinical case of HELLP syndrome involving a ruptured subcapsular liver haematoma and contextualise this with a literature overview., Clinical Case: A 39-year-old woman of 40 weeks' gestation presented to her local Emergency Department with symptoms and serology classically associated with HELLP syndrome. However, she clinically deteriorated and developed a ruptured subcapsular haematoma. She underwent an emergency Caesarean section at her initial hospital. Upon clinical stabilisation, she was transferred to our transplant unit for an urgent liver transplant., Conclusion: LT is a life-saving procedure for patients with acute liver failure secondary to HELLP syndrome. These patients should be immediately referred to a high-volume transplant centre., (Copyright © 2020. Published by Elsevier Masson SAS.)
- Published
- 2021
- Full Text
- View/download PDF
47. Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use.
- Author
-
Magro B, Zuccaro V, Novelli L, Zileri L, Celsa C, Raimondi F, Gori M, Cammà G, Battaglia S, Genova VG, Paris L, Tacelli M, Mancarella FA, Enea M, Attanasio M, Senni M, Di Marco F, Lorini LF, Fagiuoli S, Bruno R, Cammà C, and Gasbarrini A
- Subjects
- Adult, Aged, Aged, 80 and over, COVID-19 epidemiology, Cohort Studies, Female, Hospital Mortality, Hospitalization statistics & numerical data, Humans, Italy epidemiology, Male, Middle Aged, Mobile Applications, ROC Curve, Retrospective Studies, Risk Assessment methods, Risk Factors, SARS-CoV-2 isolation & purification, COVID-19 mortality
- Abstract
Backgrounds: Validated tools for predicting individual in-hospital mortality of COVID-19 are lacking. We aimed to develop and to validate a simple clinical prediction rule for early identification of in-hospital mortality of patients with COVID-19., Methods and Findings: We enrolled 2191 consecutive hospitalized patients with COVID-19 from three Italian dedicated units (derivation cohort: 1810 consecutive patients from Bergamo and Pavia units; validation cohort: 381 consecutive patients from Rome unit). The outcome was in-hospital mortality. Fine and Gray competing risks multivariate model (with discharge as a competing event) was used to develop a prediction rule for in-hospital mortality. Discrimination and calibration were assessed by the area under the receiver operating characteristic curve (AUC) and by Brier score in both the derivation and validation cohorts. Seven variables were independent risk factors for in-hospital mortality: age (Hazard Ratio [HR] 1.08, 95% Confidence Interval [CI] 1.07-1.09), male sex (HR 1.62, 95%CI 1.30-2.00), duration of symptoms before hospital admission <10 days (HR 1.72, 95%CI 1.39-2.12), diabetes (HR 1.21, 95%CI 1.02-1.45), coronary heart disease (HR 1.40 95% CI 1.09-1.80), chronic liver disease (HR 1.78, 95%CI 1.16-2.72), and lactate dehydrogenase levels at admission (HR 1.0003, 95%CI 1.0002-1.0005). The AUC was 0.822 (95%CI 0.722-0.922) in the derivation cohort and 0.820 (95%CI 0.724-0.920) in the validation cohort with good calibration. The prediction rule is freely available as a web-app (COVID-CALC: https://sites.google.com/community.unipa.it/covid-19riskpredictions/c19-rp)., Conclusions: A validated simple clinical prediction rule can promptly and accurately assess the risk for in-hospital mortality, improving triage and the management of patients with COVID-19., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
48. Biliary complications after liver transplantation: current perspectives and future strategies.
- Author
-
Magro B, Tacelli M, Mazzola A, Conti F, and Celsa C
- Abstract
Importance: Liver transplantation (LT) is a life-saving therapy for patients with end-stage liver disease and with acute liver failure, and it is associated with excellent outcomes and survival rates at 1 and 5 years. The incidence of biliary complications (BCs) after LT is reported to range from 5% to 20%, most of them occurring in the first three months, although they can occur also several years after transplantation., Objective: The aim of this review is to summarize the available evidences on pathophysiology, risk factors, diagnosis and therapeutic management of BCs after LT., Evidence Review: a literature review was performed of papers on this topic focusing on risk factors, classifications, diagnosis and treatment., Findings: Principal risk factors include surgical techniques and donor's characteristics for biliary leakage and anastomotic biliary strictures and vascular alterations for non- anastomotic biliary strictures. MRCP is the gold standard both for intra- and extrahepatic BCs, while invasive cholangiography should be restricted for therapeutic uses or when MRCP is equivocal. About treatment, endoscopic techniques are the first line of treatment with success rates of 70-100%. The combined success rate of ERCP and PTBD overcome 90% of cases. Biliary leaks often resolve spontaneously, or with the positioning of a stent in ERCP for major bile leaks., Conclusions and Relevance: BCs influence morbidity and mortality after LT, therefore further evidences are needed to identify novel possible risk factors, to understand if an immunological status that could lead to their development exists and to compare the effectiveness of innovative surgical and machine perfusion techniques., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/hbsn.2019.09.01). The authors have no conflicts of interest to declare., (2021 Hepatobiliary Surgery and Nutrition. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
49. Consequences of Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients.
- Author
-
Magro B, Mazzola A, Munteanu M, Goumard C, Martinez V, Bernard D, Scatton O, Battaglia S, Celsa C, Cammà C, and Conti F
- Subjects
- Aged, Enterobacteriaceae, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Severity of Illness Index, beta-Lactamases, End Stage Liver Disease surgery, Enterobacteriaceae Infections diagnosis, Enterobacteriaceae Infections epidemiology, Liver Transplantation, Methicillin-Resistant Staphylococcus aureus
- Abstract
Infections in patients with cirrhosis are associated with liver-related complications (LRCs), especially in patients awaiting liver transplantation (LT). The aim of this study was to evaluate the impact of methicillin-resistant Staphylococcus aureus (MRSA) and extended spectrum beta-lactamase colonization on infections and LRCs for patients on the wait list and on infections after LT. We retrospectively included 250 of 483 patients with cirrhosis who were placed on the wait list for LT from December 2015 to January 2018. These patients were screened for MRSA or extended spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) at the time of wait-list placement and after LT. Of the patients, 76% were male with a mean age of 57.5 ± 10 years, and the most frequent cause of liver disease was alcohol (39%). Median Model for End-Stage Liver Disease (MELD) score was 19 (12-28). Only 1 patient was positive for MRSA; 19% of patients (n = 47) had ESBLE fecal carriage at the time of wait-list placement and 15% (n = 37) had it after LT. Infection-free survival on the wait list and after LT, according to fecal carriage status, was not statistically different between 2 groups. LRC-free survival at 6 and 12 months was significantly lower in ESBLE fecal carriage (HR, 1.6; P = 0.04). MELD score >19 (HR, 3.0; P = 0.01) and occurrence of infection during the first 3 months on the wait list (HR, 4.13; P < 0.001) were independent risk factors for LRC occurrence in the multivariate analysis. Our study is the first showing that in a cohort of patients with cirrhosis waiting for LT LRC-free survival was lower in patients with ESBLE fecal carriage but that infection-free survival was not different between the 2 groups., (Copyright © 2020 by the American Association for the Study of Liver Diseases.)
- Published
- 2021
- Full Text
- View/download PDF
50. Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis.
- Author
-
Tacelli M, Celsa C, Magro B, Barchiesi M, Barresi L, Capurso G, Arcidiacono PG, Cammà C, and Crinò SF
- Subjects
- Endoscopic Ultrasound-Guided Fine Needle Aspiration, Endosonography, Humans, Pancreas, Pancreatic Cyst diagnostic imaging, Pancreatic Neoplasms diagnostic imaging
- Abstract
Objectives: Endoscopic ultrasound through-the-needle biopsy (EUS-TTNB) is a useful tool for differential diagnosis among pancreatic cystic lesions (PCLs). Cystic fluid cytology (CFC) is recommended by guidelines, but its diagnostic accuracy is about 50%. The aim of this meta-analysis is to assess the clinical impact of EUS-TTNB in terms of technical success (TS), histological accuracy (HA) and diagnostic yield (DY)., Methods: Original studies in English language on EUS-TTNB were searched in MEDLINE and EMBASE until October 2019. Diagnostic accuracy of EUS-TTNB for identification of mucinous PCLs was calculated using individual diagnostic data of patients who underwent CFC and surgery., Results: Nine studies, including 454 patients who underwent EUS-TTNB, met the inclusion criteria for the meta-analysis. TS and HA of EUS-TTNB were, respectively, 98.5% (95% Confidence Interval [CI] 97.3%-99.6%) and 86.7% (95%CI 80.1-93.4). DY was 69.5% (95%CI 59.2-79.7) for EUS-TTNB and 28.7% (95%CI 15.7-41.6) for CFC. Heterogeneity persisted significantly high in most of subgroup analyses. In the multivariate meta-regression, cyst size was independently associated with higher DY. Sensitivity and specificity for mucinous PCLs were 88.6 and 94.7% for EUS-TTNB, and 40 and 100% for CFC. Adverse events rate was 8.6% (95%CI 4.0-13.1)., Conclusions: This meta-analysis shows that EUS-TTNB is a feasible technique that allows a high rate of adequate specimens to be obtained for histology; in about two-thirds of patients a specific histotype diagnosis could be assessed. The number of adverse events is slightly higher respect to standard EUS-FNA, but complications are very rarely severe., (© 2020 Japan Gastroenterological Endoscopy Society.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.